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AbstrACt
Introduction Haemophilia is a bleeding disorder 
associated with significant pain, emotional distress, quality 
of life (QoL) impairment and considerable healthcare costs. 
Psychosocial health and effective pain management are 
considered essential end points for optimal haemophilia 
care, but there is a significant gap in evidence-based 
treatments targeting these outcomes in people with 
haemophilia (PWH). Psychological interventions are cost-
effective in promoting emotional well-being, QoL and 
pain control, although these have been scarcely used in 
haemophilia field. This investigation aims to evaluate the 
effectiveness of two psychological interventions for pain 
management, emotional regulation and promotion of QoL 
in PWH.
Methods and analysis This is a single-centre parallel 
randomised controlled trial conducted at a European 
Haemophilia Comprehensive Care Centre in Portugal, with 
five assessment points: baseline (T0), postintervention 
(T1), 3 (T2), 6 (T3) and 12 (T4) months follow-up. Eligible 
adult males, with moderate or severe haemophilia A or B 
will be randomised to experimental (EG) or control (CG) 
group. Intervention is either cognitive-behavioural therapy 
(EG1) or hypnosis (EG2), both consisting of four weekly 
sessions following standardised scripts delivered by trained 
psychologists. Randomisation will be computer generated, 
allocation concealment will be guaranteed and outcome 
assessors will be blind to EG/CG allocation. Main outcomes 
are pain and haemophilia-related QoL and secondary 
outcomes include clinical (clotting factor replacement 
consumption, joint bleeding episodes, analgesic intake) and 
psychological (pain coping strategies, anxiety, depression, 
illness perceptions) variables, functional assessment of the 
joints, inflammatory biomarkers (cytokines, high-sensitivity 
C reactive protein) and white blood cell count.
Ethics and dissemination This study was approved 
by the competent authorities and all procedures will 
comply with international ethical guidelines for clinical 
studies involving humans. Written informed consent will 
be obtained from all participants. The dissemination plan 
includes peer-reviewed scientific publications, conference 
participation and web and media coverage.
trial registration number NCT02870452.
bACkground And rAtIonAl
Haemophilia is an inherited X-linked 
bleeding disorder caused by a deficiency in 
coagulation factor VIII (haemophilia A) or 
IX (haemophilia B). Due to this deficit in 
strengths and limitations of this study
 ► This is an innovative investigation, applying 
two empirically sound interventions (cognitive-
behavioural therapy and hypnosis) to people with 
haemophilia.
 ► SPIRIT (Standard Protocol Items Recommendations 
for Interventional Trials) checklist guidelines were 
followed, to ensure quality in all aspects of study 
planning and execution.
 ► Random allocation and specific efforts to limit bias 
(blinded outcome assessment, standardisation 
of intervention and collection of concomitant 
treatment) contribute to strengthen the study.
 ► Main limitation of this randomised controlled 
trial is being a single-centre study, limiting the 
generalisability of potential findings.
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coagulation factor, the main clinical manifestation of 
haemophilia is an increased bleeding tendency, either 
spontaneous or related to trauma or surgery. Spon-
taneous bleeding episodes occur mainly in the joints 
(haemarthrosis) and, if recurrent, lead to persistent joint 
damage and development of chronic joint arthropathy 
(haemophilic arthropathy).1 Severity of haemophilia is 
classified according to clotting factor level, being defined 
as mild (clotting factor between 5% and 40% of normal), 
moderate (1%–5% of normal clotting factor) or severe 
(clotting factor level under 1% of normal), which gener-
ally correlates to a correspondent increase in bleeding 
frequency.2
Given the clinical presentation of haemophilia, the 
main goal of care is prevention and treatment of bleeds, 
which is mainly achieved through different modalities 
of clotting factor replacement therapy. However, recent 
guidelines have also highlighted the importance of 
considering psychosocial health and quality of life (QoL) 
as important outcomes for optimal care among people 
with haemophilia (PWH).3 4 In fact, PWH have particular 
psychological and social needs related to haemophil-
ia-specific threats and challenges, such as pain and daily 
living restrictions,5 which impact significantly on QoL.6 
Therefore, the focus of current haemophilia manage-
ment practise is to minimise joint disease and to simulta-
neously increase QoL.7
In this context, a very relevant issue is pain, which is a 
common, highly debilitating feature of haemophilia that 
has been related with decreased QoL.8 PWH experience 
acute pain during haemarthrosis, but might also report 
chronic pain resulting from haemophilic arthropathy.1 9 
On a recent 10 country survey, chronic pain related to 
haemophilia was reported by 38% of the respondents, 
highlighting the high prevalence of this condition among 
PWH.4 Nevertheless, patient reports also account for 
suboptimal pain management, with 33%–39% of patients 
in the USA and Europe reporting dissatisfaction with 
current pain treatment.4 10–12 This question is such an 
important issue that, in an editorial, Humphries and 
Kessler13emphasise that the improvement of pain assess-
ment, prevention and control is a key end point in the 
development of future treatments for PWH. In sum, 
pain control should be a priority in haemophilia treat-
ment,13 focusing on chronic pain management, and on 
its prevention, as recommended by international guide-
lines, which state that non-pharmacological treatments, 
such as psychological interventions, should be consid-
ered for both these purposes.8 10 However, despite well-es-
tablished recommendations, there is still a scarcity of 
evidence-based treatment guidelines for haemophilia 
pain management. This is one important limitation to 
treatment progress in this field, justifying the need to 
conduct robust intervention-type investigations in this 
population.8
Another noteworthy issue is that psychological or 
psychiatric conditions are reported by 47% of PWH, with 
29% relating these symptoms to haemophilia.4 This is 
even more relevant considering that psychological factors 
can influence both pain experience and QoL in PWH.12 
Interestingly, Cassis et al6 state that variations in QoL are 
better explained by psychosocial, rather than clinical 
predictors. Since the former are potentially modifiable 
through psychological interventions, there is a recognised 
need to design interventions targeting social and psycho-
logical aspects of PWH.14
Indeed, psychological interventions have been proven to 
be effective in a broad range of disorders and illnesses.15–18 
Although a few former works have focused on psycholog-
ical interventions in haemophilia, showing positive and 
promising results,19–25 the lack of recent papers exploring 
this issue is somewhat surprising, despite the recommen-
dations and guidelines that emphasise their relevance. In 
those publications, a blend of psychological techniques 
was applied, with particular emphasis on hypnosis.19 20 24 25 
In fact, there is considerable evidence for the effective-
ness of hypnosis as an empirically supported clinical inter-
vention in managing symptoms such as pain,26–35 and also 
in promoting psychological well-being across a variety of 
illnesses and disorders.36–43 Among PWH, studies have 
shown that hypnosis can contribute to control pain and 
to reduce frequency and severity of bleedings and factor 
consumption.19 20 24 Concurrently, by promoting better 
disease management, hypnosis can contribute to better 
coping and less distress.24
Besides hypnosis, cognitive-behavioural therapy is 
another psychological strategy commonly used in health-
care contexts. This has been the gold standard of psycho-
logical intervention, with recognised effectiveness in 
reducing negative emotions such as anxiety and depres-
sion, as well as in managing pain and promoting QoL in 
chronic disease.15 17 44–48 Nevertheless, and to the best of 
our knowledge, it was never fully applied to haemophilia 
field.
In sum, and despite the shortage of studies focused 
on psychological interventions in haemophilia, these 
are recognised as complementary non-pharmacological 
therapies and as a valuable resource to expand haemo-
philia care and potentially maximise treatment outcomes, 
promoting QoL and emotional well-being and improving 
symptoms management.12 14
Another relevant issue in the field of haemophilia 
concerns inflammatory biomarkers, such as cytokines 
and high-sensitivity C reactive protein (hs-CRP), given 
their recognised role in inflammatory and degenerative 
processes that are related to the development of haemo-
philic arthropathy.49 For instance, pro-inflammatory 
(eg, interleukin (IL)-6, IL-1β, tumour necrosis factor 
(TNF)-α) and anti-inflammatory (eg, IL-10) cytokines 
have been implicated in the pathophysiology of haemo-
philic arthropathy, joint pain-associated nociceptive 
pathways and inhibitor development.49–56 In addition, 
these biomarkers have also been shown to be correlates 
of psychological variables and, therefore, physiological 
approaches could support the potential efficacy of psycho-
logical interventions on disease and pain control.57–59
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This is particularly relevant in light of the attention 
being given to psychosocial health in haemophilia, which 
has been advocated as a priority in the improvement of 
health status and QoL in PWH.4 60 To this purpose, it is 
recommended that comprehensive care teams should 
be multidisciplinary and include a psychosocial expert, 
who can provide complete assessment of psychosocial 
status and contribute to an integrated disease manage-
ment plan.3 Globally, integrated care models are 
preferred over non-integrated care models, but there is 
still some uncertainty concerning which aspects of care 
might improve haemophilia management and patient 
outcomes, and what is the ideal composition of haemo-
philia care services.61 Thus, there is an important gap 
between the need to clarify these issues and the lack of 
recent studies analysing psychological interventions for 
PWH. This, added to the psychosocial impact of haemo-
philia discussed above, validates the need to advance 
research in this field, namely through the planning and 
implementation of clinical randomised controlled trials 
(RCTs) that test the effectiveness of distinct psychological 
interventions. In addition, it is noteworthy that, despite 
pain being recognised as an important consequence of 
bleeding disorders, it has not been taken into account in 
most clinical trials of haemophilia.13
The current study protocol points to an innovative 
research that can contribute to better understand the 
impact and potential benefits of psychological interven-
tions in haemophilia care setting. Given the negative 
impact of haemophilia on individual QoL and the asso-
ciated healthcare costs, it is mandatory to evaluate the 
effectiveness of theoretically grounded psychological 
interventions in this field.
objECtIvE
The primary objective of this study is to evaluate the 
relative effectiveness of two psychological interventions, 
cognitive-behavioural therapy (CBT) and hypnosis 
(HYP), in order to manage pain, promote emotional 
regulation and improve QoL, among adult Portuguese 
men with haemophilia.
Methods
Trial design
The design of this study follows the recommendations of 
Yates et al62 concerning psychological trials for pain, and 
reporting of the study results will follow Consolidated 
Standards of Reporting Trials (CONSORT) guidelines for 
trials of non-pharmacological interventions.63
This is a single-centre three-arm parallel prospective 
RCT, with one control group (CG) and two experimental 
groups: CBT and HyP, using an expertise-based RCT 
design. Participants in both groups will be followed longi-
tudinally, in five time assessment points:
T0: Baseline assessment (preintervention, before 
randomisation).
T1: Post-test assessment (1 week after intervention).
T2: Follow-up assessment 1 (3 months after 
intervention).
T3: Follow-up assessment 2 (6 months after 
intervention).
T4: Follow-up assessment 3 (12 months after 
intervention).
Participants and procedures
According to sample size calculation, 66 patients will 
enter the study. Estimations were made using G*Power 
V.3.1.9 and considering the following assumptions: to 
perform a one-way analysis of variance (ANOVA) with 
fixed effects, large effect size (f=0.4), significance level 
(α—type I error) of 0.05 and statistical power (1-β—type 
II error) of 0.80.
Participants will be recruited at the European Haemo-
philia Comprehensive Care Centre of São João Hospital 
Center, in Porto, Portugal. Eligible patients will be iden-
tified by the clinicians of the Haemophilia Centre and 
invited to participate if they comply with the following 
inclusion criteria: (a) male gender; (b) age ≥18 years; 
(c) diagnosis of moderate or severe haemophilia A or B, 
with or without inhibitors; (d) diagnostic of haemophilic 
arthropathy in at least one joint; (e) chronic pain, as 
defined by the European Haemophilia Therapy Standard-
isation Board (EHTSB)10; (f) ability to consent voluntary 
participation to the study; (g) ability to read and write.
The exclusion criteria are: (a) severe and debilitating 
neurological conditions (eg, dementia); (b) severe 
psychiatric conditions (eg, schizophrenia); (c) currently 
undergoing any form of psychotherapy; (d) unavailability 
to commit to four weekly sessions.
Patients willing to enrol will be screened by the clini-
cians to assess inclusion criteria and later referred to the 
investigators, who will describe and explain the study’s 
objectives and interventions and clarify any concern or 
doubt, emphasising confidentiality and voluntary nature 
of participation. After acceptance, patients sign the 
informed consent and baseline assessment is performed 
(T0). After baseline assessment, participants are randomly 
assigned to one of the three groups (CBT, HyP or CG) 
and, for patients in CBT and HyP groups, four weekly indi-
vidual intervention sessions are scheduled. On the fifth 
week, all the patients are assessed for post-test assessment 
(T1). Follow-up assessments will take place at 3 (T2), 6 
(T3) and 12 (T4) months after intervention ending for 
all participants (CBT, HyP and CG). Participant time-
line for enrolment, intervention and assessment points is 
schematised in figure 1.
randomisation and allocation
Randomisation procedures will follow a stratified blocked 
randomisation process using a computerised random 
sequence generator. In order to control for potential 
confounding effects, stratification will be done by haemo-
philia severity. The generated sequence will be concealed 
and patient allocation will not be revealed until official 
enrolment, after consent is given and baseline assessment 
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is completed. One of a series of consecutively numbered 
sealed opaque envelopes with group allocation will be 
opened at this moment and revealed to the patient. Due to 
obvious differences in procedure, blinding of the patients 
to intervention versus control group is impossible. More-
over, it is possible that some patients are familiar with 
psychological intervention strategies and are able to recog-
nise their allocated intervention and, therefore, blinding to 
type of psychological intervention (CBT vs HyP) cannot be 
guaranteed. However, in order to prevent further bias, the 
type of intervention will not be disclosed to the patients. 
The different randomisation steps (sequence generation 
and patient allocation) will be performed independently by 
the two investigators conducting the intervention sessions, 
who are aware of patients’ allocated arm. Information 
concerning allocation is concealed from the investigator 
performing subsequent outcome assessment. There are 
no anticipated circumstances to justify unblinding of any 
parties for the duration of the trial, or discontinuation of 
intervention.
Intervention groups
The two experimental conditions (CBT/HyP) have the 
same format of four consecutive weekly sessions of psycho-
logical intervention, scheduled following T0 assessment. 
Two doctorate-level health psychologists will conduct 
these groups individually, in a private and quiet room. 
Due to the nature of the interventions, each psychologist 
will perform only one type of intervention (CBT/HyP), 
based on training and expertise.
Specific scripts and manuals will be created for each 
intervention modality, based on theoretical and empirical 
foundations and taking into account the specificities of 
haemophilia, its treatment and associated complications.
Strategies to promote participant retention and adher-
ence to intervention and follow-up assessment sessions 
will include careful explanation of the study and expected 
benefits, session scheduling according to individual prefer-
ences and reminder telephone calls prior to intervention 
or assessment sessions. In order to control for cointerven-
tion bias in the reported outcomes, all concomitant care 
(clotting factor replacement consumption, analgesics and 
other medications, medical exams, physical therapy, ice, 
rest, etc) will be closely monitored, either by self-report or 
by collecting information from clinical records.
There are no anticipated adverse effects associated with 
the psychological interventions and/or assessment proce-
dures, but their unlikely occurrence will be carefully 
monitored.
Figure 1 Trial design. CBT, cognitive-behavioural therapy; CG, control group; HyP, hypnosis.
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Experimental group 1: CBT
According to this model, thoughts, beliefs, attributions 
and expectations play a key role in the perception of 
disease-related symptoms, such as pain, and in how 
people adjust to them.64 The underlying process advo-
cates a strong link between such cognitions and emotional 
state, physical symptoms and behaviours. Thus, alarming, 
self-defeating and unrealistic thoughts contribute to 
negative emotions and behaviour (maladaptive coping 
responses) while realistic and more reassuring thoughts 
lead to more positive emotions and behaviour (adaptive 
coping responses).65 66
Furthermore, CBT is a comprehensive approach and 
enables patients to integrate information on biological, 
psychological and social influences about disease-relat-
ed-symptoms,64 thereby enhancing their understanding 
on how the mind and body work together to influence the 
course of disease and the concomitant pain experience.
This protocol comprises four sessions, one educative and 
three focused on adaptive coping skills training, wherein 
active and structured techniques are taught, embracing 
coping with haemophilia-specific threats, challenges and 
symptoms flare-ups (eg, bleedings and pain), goal-setting, 
distraction, relaxation and problem-solving skills.
In this scope, the following contents and strategies will 
be approached: (1) educational rationale concerning 
the theoretical assumptions of CBT model, haemophilia 
characteristics and pain experience (conceptualised as a 
multidimensional subjective experience, resulting from a 
dynamic and complex interaction among psychological, 
biological and social dimensions); (2) cognitive restruc-
turing, with instruction and practise on the identification, 
challenging and replacing of negative and self-defeating 
automatic thoughts that may impact on haemophilia 
symptoms, pain and psychological distress; (3) prob-
lem-solving skills, providing patients with an opportunity 
to deal with the constraints, consequences and impli-
cations of haemophilia and (4) relaxation techniques, 
coupled with attention diversion strategies.
Simultaneously, patients will be encouraged to work 
toward overall behavioural goals through homework assign-
ments (eg, keep a symptom diary to identify triggers of 
emotional distress or schedule daily pleasant activities).
Experimental group 2: HyP
Hypnosis is a psychotherapeutic technique in which the 
person is guided by the hypnotist to respond to sugges-
tions for alterations in subjective experience, such as 
changes in sensations, perceptions, emotions, cognitions 
or behaviours.41 67 It includes elements such as relaxation, 
focused attention, imagery, interpersonal processing and 
suggestion.68
Hypnosis interventions usually comprise the following 
stages: introduction/preparation of the patient (explaining 
the rationale underlying hypnosis, including dispelling 
potential myths, misconceptions and doubts); hypnotic 
induction (suggestions to promote a state of relaxation 
and focused awareness); imagery (eg, imagining oneself 
as being in an agreeable and comfortable place); deep-
ening procedure (further suggestions for achieving a more 
deeply relaxed and focused state); symptom-specific ther-
apeutic suggestions (specific for each illness or disorder, 
aiming to change or improve symptoms and/or maladap-
tive behaviours) and conclusion.41 Before concluding 
the process, posthypnotic suggestions might be made, to 
extend the benefits obtained beyond the session setting. In 
this line, providing patients with means to perform hypnosis 
independently by themselves (self-hypnosis) assists in the 
reinforcement of those posthypnotic suggestions. Indeed, 
self-hypnosis constitutes a powerful resource that guaran-
tees the practise of the technique, independently and in 
an autonomous fashion, thereby empowering patients and 
giving them a sense of control and mastery over their prob-
lems and their lives.30 65
Within this four-session hypnosis intervention, tech-
niques will range from specific direct suggestions for 
symptom control following hypnotic induction, to a 
complex sequence of suggestions and metaphors for 
relaxation, guided imagery, ego strengthening, dissocia-
tion and well-being.
In order to engage patients in hypnosis, the first step is to 
explain its principles, providing patients with a rationale for 
its learning and use. Moreover, and similarly to what occurs 
in CBT intervention, the explanation of haemophilia char-
acteristics and pain neurophysiology will be highlighted, 
emphasising that pain results from a complex and dynamic 
interplay between biological processes and psycholog-
ical factors (cognitive and emotional). Symptom-specific 
suggestions will address haemophilia-specific challenges 
and threats, treatment-related difficulties, stress-producing 
situations, bleedings, pain and the emotional reactions to 
these symptoms, as well as haemophilia adjustment. Specif-
ically concerning pain, the hypnotic suggestions will focus 
on deep relaxation, sensory substitution, pain intensity 
reduction, imagined anaesthesia and analgesia (skills for 
glove analgesia and transfer), decreased pain unpleas-
antness, managing breakthrough pain and posthypnotic 
suggestions for effective self-hypnosis.66 All suggestions are 
made on a repetitive basis at each session and all sessions 
will end with posthypnotic suggestions, underscoring that 
any experience of well-being, healing and comfort obtained 
will remain with the patient and last beyond the sessions, 
becoming a permanent part of how the patient lives life and 
cope with disease and problematic issues.
To promote the usage and customisation of self-hyp-
nosis, patients will also be given a CD of the session, and 
encouraged to practise self-hypnosis outside the sessions, 
at least on a daily basis.
Control group
Patients in the CG will receive medical treatments and 
standard care as usual. Assessments will be made in all 
the same five assessment time points as with EG partici-
pants, but without receiving any psychological interven-
tion. At the end of the study, these patients will be given 
the opportunity to participate in four sessions of the 
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intervention that would prove to be most effective at the 
end of this investigation.
outcome measures (see table 1)
Primary outcome measures
Pain experience (frequency, intensity and interference) 
and haemophilia-related QoL, assessed after intervention 
(T1) and in the follow-up assessments of 3 (T2), 6 (T3) 
and 12 months (T4) after intervention ending.
Secondary outcome measures
 ► Clinical: clotting factor replacement consumption 
(IU/kg/week), joint bleeding episodes and analgesic 
intake (type, dosage and frequency) assessed at T1, 
T2, T3 and T4.
 ► Psychological: anxiety, depression, pain coping strat-
egies and illness perceptions, assessed at T1, T2, T3 
and T4.
 ► Functional: assessment of the joints evaluated at T2 
and T4.
 ► Physiological: inflammatory biomarkers—cytokines 
(pro-inflammatory (IL-1β, TNF-α, IL-6) and anti-in-
flammatory (IL-10)), hs-CRP and WBC count assessed 
at T2 and T4.
Other variables
 ► Sociodemographic (eg, age, professional status) and 
clinical variables (eg, inhibitor status, prophylaxis) 
will be taken into account as potential mediators or 
moderators for the influence of independent varia-
bles (type of intervention) on outcome measures.
 ► Hypnotic susceptibility will be assessed in all patients 
at baseline (T0) using the Stanford Hypnotic Suscep-
tibility Scale.69
Data collection
All data collection procedures (demographic, clinical, 
psychological and physiological) will be conducted by 
trained and experienced healthcare providers. In order to 
avoid interassessor subjectivity, assessment of the joints will 
be performed by the same physician, an orthopaedist with 
experience and training in haemophilia care. To ensure the 
quality of self-reported data, the psychological assessment 
will be performed by the same investigator, a trained health 
psychologist experienced in psychological evaluation proce-
dures. Blood samples will be collected by trained nurses.
Assessment measures
Sociodemographic information
- Sociodemographic questionnaire (developed by the research 
team): collects patients’ data concerning age, education, 
marital status, professional status, household, etc.
Clinical and pain assessment
 ► Clinical questionnaire (developed by the research 
team): gathers general clinical information about 
patients’ haemophilia status, such as type and 
severity, age at time of diagnosis, type and frequency 
of medical treatments, clotting factor replacement 
consumption, inhibitor status, joint bleeding episodes 
and comorbidities.
 ► Multidimensional Haemophilia Pain Questionnaire 
(MHPQ): developed by the research team to assess 
haemophilia-related pain, following published 
guidelines for haemophilia pain assessment10 and 
intending to fill a gap in existing pain assessment tools 
for PWH.13 Questionnaire development was based on 
an extensive literature review, expert opinion, pilot 
studying and further refinement of item content and 
wording. It is currently going through the validation 
process, after being used in its experimental version 
on the first Portuguese haemophilia national survey 
conducted by our team.
The MHPQ has 26 items regarding haemophilia-related 
pain experienced in the previous year. Four items assess 
the presence of chronic pain according to the EHTSB 
guidelines, defined as continuous and/or intermittent 
pain, related to the pathophysiology of haemophilia 
and requiring pharmacological or non-pharmacological 
intervention, in which the cause of pain cannot be readily 
removed, which occurs more than once a week and lasts 3 
months or more.10 The remaining questions are divided 
in nine dimensions:
Painful locations: asks about haemophilia-related pain 
locations, specifying the most painful location and the 
one which caused the greatest impact.
Duration: assesses how long ago the pain with greatest 
impact started.
Frequency: evaluates how often the pain is present and 
when was the last time it occurred.
Triggering factors (and temporal pattern): requires the 
selection, from a list, of haemophilia pain potential 
triggers, such as: bleeds, climbing stairs or weather 
changes, specifying the daytime when pain is most often 
experienced.
Intensity: measured in regard to specific situations, 
such as during bleeds, while in rest or during movement, 
through a 0–10 Numerical Rating Scale (NRS) (0=no 
pain; 10=worst imaginable pain).
Interference: these items were drawn from the Brief 
Pain Inventory’s interference subscale,70 evaluating pain 
interference with general activity, mood, walking ability, 
normal work, relations with people, sleep and enjoyment 
of life, assessed according to a NRS (0=no interference; 
10=completely interferes).
Strategies for pain control: several strategies are presented 
(factor replacement, rest, ice, analgesics, distracting, etc) 
for people to mark the ones they usually do or ever did 
and the degree of relief they provide (0%–100% scale).
Pain management specialists: asks about pain specialists 
people have or would like to consult to help manage pain 
(eg, haemophilia doctors, anaesthesiologists, psycholo-
gists, professionals of alternative therapies, etc).
Satisfaction with pain treatment: evaluates global satisfac-
tion with pain treatment through a single question, on a 
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5-point scale (ranging from 1=‘very dissatisfied’ to 5=‘very 
satisfied’).
Each dimension in analysed separately and no global 
pain score is computed for the MHPQ.
Psychological assessment
The Portuguese versions of the following questionnaires 
will be used.
 ► A36Hemofilia-Qol71: this is an haemophilia-specific 
self-report questionnaire assessing health-related 
QoL. The 36 items are divided in 9 subscales: physical 
health; daily activities; joints; pain; treatment satisfac-
tion; treatment difficulties; emotional functioning; 
mental health and relationships and social activity. 
A total score can also be computed. The A36Hemo-
filia-Qol was originally developed and validated in 
Spain with good validity and reliability properties.71 
The Portuguese version was created following a 
complete translation back-translation process by 
certified translators. Similar to the above-mentioned 
MHPQ, it is currently going through the validation 
process.
 ► Hospital Anxiety and Depression Scale72: assesses anxiety 
and depression in two separate subscales with seven 
items each. Scoring in each item ranges from 0 to 3, 
with a total possible score varying from 0 to 21. Higher 
scores translate higher levels of anxiety and depres-
sion. This questionnaire was developed in a hospital 
outpatient clinic, avoiding questions that could be 
influenced by physical illness symptoms72 and has 
since been found a reliable measure of anxiety and 
depression symptom severity in physical and psychi-
atric illness, primary care patients and general popula-
tion.73 It has been validated for Portuguese patients.74
 ► Coping Strategies Questionnaire-Revised Form (CSQ-R)75: 
includes 27 items that represent different coping strat-
egies people usually use when in pain. It is organised in 
six subscales: distraction/diverting attention; praying 
and hoping; ignoring pain sensations; reinterpreting 
pain sensations; pain-coping self-statements and pain 
catastrophising. The Portuguese version applied in 
this study has been used in several investigations in 
hospital setting with good reliability properties.76–78
 ► Illness Perception Questionnaire (IPQ-R)79: assesses 
patients beliefs about their illness, according to seven 
dimensions: timeline acute/chronic; timeline cyclical; 
consequences; personal control; treatment control; 
illness coherence; emotional representation. The 
IPQ-R has been validated for Portugal80 and, in this 
study, participants will be evaluated with a psycho-
metrically shortened version of 21 items,81 previously 
used in Portuguese clinical setting,76–78 to reduce 
respondent burden.
Physiological assessment
This will be performed through the collection of blood 
samples in order to conduct WBC count and to achieve 
a systemic evaluation of pro-inflammatory (IL-6, IL-1β, 
TNF-α) and anti-inflammatory cytokines (IL-10), as well 
as of hs-CRP.
On arrival at the Haemophilia Centre (between 09:30 
and 1:30 hours), patients will undergo sample blood 
collection and EDTA samples will be transported immedi-
ately to the lab. In the lab, blood samples are centrifuged 
15 min at 3000 rpm, and plasma aliquoted and stored in 
a freezer at −70°C, until further analysis. Plasma levels of 
cytokines (IL-6, IL-1β, TNF-α, IL-10) are assayed in dupli-
cate using ultrasensitive multiplex human ELISA kits 
(Life Technologies).
Functional assessment
 ► WFH Physical Examination Score (Gilbert Score)82: 
rates joint impairment based on clinical evaluation 
of joints, considering physical status evaluation and 
reported pain. Physical examination includes assess-
ment of swelling, muscle atrophy, axial deformity, 
crepitus on motion, range of motion, flexion contrac-
ture and instability.
 ► Pettersson Score83: assesses joints quantitatively, based on 
the presence or absence of radiographic changes in 
eight dimensions: osteoporosis, enlargement of epiph-
ysis, irregularity of subchondral surface, narrowing 
of joint space, subchondral cysts formation, erosion 
of joint margins, gross incongruence of articulating 
bone ends and joint deformity (angulation and/or 
displacement between articulating bones).
Data analysis plan
All data analysis procedures will be performed using IBM 
SPSS Statistics V.24 (SPSS, Chicago, Illinois, USA), except 
for sample size estimation, that will be calculated with 
G*Power V.3.1.9, as described above.
The analysis plan will follow intention-to-treat princi-
ples (all participants as randomised). Frequencies and 
descriptive statistics (means, SD, skewness and kurtosis) 
will be analysed for sample characteristics at baseline 
and for outcome measures in the five assessment points. 
A mixed ANOVA will be performed to test mean differ-
ences between the three groups (CBT vs HyP vs CG; 
between-subject factor) over the five measurement points 
(within-subjects factor). This procedure allows the test of 
main group/intervention and time effects and mainly if 
there is a significant interaction effect between the two 
factors (between and the within subjects).
At the end of the study, it will be possible to determine 
if changes in outcomes (eg, QoL) over time depend on 
the intervention. If no significant interaction effects are 
obtained, it can be concluded that changes in outcomes 
were simply due to time. Effect size measures (partial eta 
squared) and statistical power (1-β) will be presented for 
all statistical tests performed. Results will be considered 
significant for p values <0.05.
Since all data collection procedures will be conducted 
in-person, there is no anticipated missing data for base-
line or subsequent assessments. In the case of missing 
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values existence, missing value analysis will be performed 
to determine if missing observations are: a) completely at 
random (MCAR) or b) at random (MAR). Missing values 
replacement will be performed accordingly (MCAR or 
MAR) using multiple imputation84 performed using the 
IBM SPSS Amos V.24.
EthICs And dIssEMInAtIon
This investigation will submit to international ethical 
principles and guidelines for clinical studies involving 
humans. All participants will read and sign the informed 
consent and all doubts and questions will be addressed 
by the research team. Study-related data will be stored in 
locked cabinets and limited access, password protected 
computers and confidentiality will be guaranteed by 
assigning a code to each participant. An anonymised 
final version of the dataset will be available to team 
members.
The study was authorised by the Portuguese National 
Data Protection Agency (CNPD) and approved by the 
Life Sciences and Health Ethics Subcommittee—Univer-
sity of Minho, and by the Centro Hospitalar de São 
João—E.P.E. Ethics Committee. Any modification to the 
research protocol will be communicated in the  clinical-
trials. gov RCT registry. Final conclusions of this investi-
gation will be published in peer-reviewed journals and 
presented at haemophilia international conferences, 
and made available to the PWH community through 
appropriate channels (national news channels, web and 
social media).
Author affiliations
1Life and Health Sciences Research Institute, School of Medicine, University of 
Minho, Braga, Portugal
2ICVS / 3B’s, PT Government Associate Laboratory, Braga / Guimarães, Portugal
9Faculty of Psychology and Education Sciences, University of Porto, Porto, Portugal
10Centre of Hemophilia, Department of Transfusion Medicine and Blood Bank, 
Centro Hospitalar São João, Porto, Portugal
11School of Psychology, University of Minho, Braga, Portugal
Contributors PRP conceived the study idea and together with SP developed the 
design and created the intervention manuals. ACP and AA substantially contributed 
for the development and refinement of the study protocol. MC, ML and SF 
contributed for the refinement of the design with clinical expertise. PC supervised 
the power analyses and planned the data analysis. All authors participated in 
the drafting of this paper and critically revised and approved the final version. All 
authors are accountable for any issue regarding the accuracy and integrity of the 
work.
Funding This work is supported by a grant from the Novo Nordisk HERO Research 
Grant 2015. PRP has a grant (SFRH/BPD/103529/2014) from the Portuguese 
Foundation of Science and Technology.
Competing interests None declared.
Patient consent Detail has been removed from this case description/these case 
descriptions to ensure anonymity. The editors and reviewers have seen the detailed 
information available and are satisfied that the information backs up the case the 
authors are making.
Ethics approval Life Sciences and Health Ethics Subcommittee, University of 
Minho; Health Ethics Committee Centro Hospitalar São João.
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEnCEs
 1. Lobet S, Hermans C, Lambert C. Optimal management of hemophilic 
arthropathy and hematomas. J Blood Med 2014;5:207–18.
 2. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: 
communication from the SSC of the ISTH. J Thromb Haemost 
2014;12:1935–9.
 3. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines 
for the management of hemophilia. Haemophilia 2013;19:e1–e47.
 4. Forsyth AL, Gregory M, Nugent D, et al. Haemophilia experiences, 
results and Opportunities (HERO) Study: survey methodology and 
population demographics. Haemophilia 2014;20:44–51.
 5. De Moerloose P, Fischer K, Lambert T, et al. Recommendations for 
assessment, monitoring and follow-up of patients with haemophilia. 
Haemophilia 2012;18:319–25.
 6. Cassis FR, Querol F, Forsyth A, et al. Psychosocial aspects of 
haemophilia: a systematic review of methodologies and findings. 
Haemophilia 2012;18:e101–e114.
 7. Raffini L, Manno C. Modern management of haemophilic arthropathy. 
Br J Haematol 2007;136:777–87.
 8. Riley RR, Witkop M, Hellman E, et al. Assessment and management 
of pain in haemophilia patients. Haemophilia 2011;17:839–45.
 9. Merskey HE. Classification of chronic pain: descriptions of chronic 
pain syndromes and definitions of pain terms. Pain, 1986. http://
www. iasp- pain. org/ files/ Content/ ContentFolders/ Publications2/ 
FreeBooks/ Classification- of- Chronic- Pain. pdf.
 10. Holstein K, Klamroth R, Richards M, et al. Pain management 
in patients with haemophilia: a European survey. Haemophilia 
2012;18:743–52.
 11. Witkop M, Lambing A, Divine G, et al. A national study of pain in the 
bleeding disorders community: a description of haemophilia pain. 
Haemophilia 2012;18:e115–e119.
 12. Young G, Tachdjian R, Baumann K, et al. Comprehensive 
management of chronic pain in haemophilia. Haemophilia 
2014;20:e113–e120.
 13. Humphries TJ, Kessler CM. Pain in haemophilia: are we listening? 
Haemophilia 2016;22:175–8.
 14. Cassis F, Emiliani F, Pasi J, et al. Psychological interventions 
for people with hemophilia. Cochrane Database Syst Rev 
2012;11:CD010215.
 15. Carlson LE, Bultz BD. Efficacy and medical cost offset of 
psychosocial interventions in cancer care: making the case for 
economic analyses. Psychooncology 2004;13:837–49.
 16. Crane DR, Christenson JD. The Medical Offset effect: patterns in 
Outpatient Services Reduction for High Utilizers of Health Care. 
Contemp Fam Ther 2008;30:127–38.
 17. Williams AC, Eccleston C, Morley S. Psychological therapies for 
the management of chronic pain (excluding headache) in adults. 
Cochrane Database Syst Rev 2012;11:CD007407.
 18. Frederiksen Y, Farver-Vestergaard I, Skovgård NG, et al. Efficacy 
of psychosocial interventions for psychological and pregnancy 
outcomes in infertile women and men: a systematic review and 
meta-analysis. BMJ Open 2015;5:e006592.
 19. LaBaw WL. Auto-hypnosis in haemophilia. Haematologia 1975;9(1-
2):103–10.
 20. Lucas ON. The use of hypnosis in Hemofilia dental care. Ann N Y 
Acad Sci 1975;20:263–6.
 21. Varni JW. Behavioral medicine in hemophilia arthritic pain 
management: two case studies. Arch Phys Med Rehabil 
1981;62:183–7.
 22. Varni JW. Self-regulation techniques in the management of chronic 
arthritic pain in hemophilia. Behav Ther 1981;12:185–94.
 23. Varni JW, Gilbert A. Self-regulation of chronic arthritic pain and long-
term analgesic dependence in a haemophiliac. Rheumatol Rehabil 
1982;21:171–4.
 24. Swirsky-Sacchetti T, Margolis CG. The effects of a comprehensive 
self-hypnosis training program on the use of factor VIII in severe 
hemophilia. Int J Clin Exp Hypn 1986;34:71–83.
 25. LaBaw W. The use of hypnosis with hemophilia. Psychiatr Med 
1992;10:89–98.
10 Pinto PR, et al. BMJ Open 2017;7:e016973. doi:10.1136/bmjopen-2017-016973
Open Access 
 26. Montgomery GH, DuHamel KN, Redd WH. A meta-analysis of 
hypnotically induced analgesia: how effective is hypnosis? Int J Clin 
Exp Hypn 2000;48:138–53.
 27. Montgomery GH, David D, Winkel G, et al. The effectiveness of 
adjunctive hypnosis with surgical patients: a meta-analysis. Anesth 
Analg 2002;94:1639–45.
 28. Lang EV, Rosen MP. Cost analysis of adjunct hypnosis with sedation 
during outpatient interventional radiologic procedures. Radiology 
2002;222:375–82.
 29. Patterson DR, Jensen MP. Hypnosis and clinical pain. Psychol Bull 
2003;129:495–521.
 30. Jensen M, Patterson DR. Hypnotic treatment of chronic pain. J 
Behav Med 2006;29:95–124.
 31. Elkins G, Jensen MP, Patterson DR. Hypnotherapy for the 
management of chronic pain. Int J Clin Exp Hypn 2007;55:275–87.
 32. Stoelb BL, Molton IR, Jensen MP, et al. The efficacy of hypnotic 
analgesia in adults: a review of the literature. Contemp Hypn 
2009;26:24–39.
 33. Tefikow S, Barth J, Maichrowitz S, et al. Efficacy of hypnosis in 
adults undergoing surgery or medical procedures: a meta-analysis of 
randomized controlled trials. Clin Psychol Rev 2013;33:623–36.
 34. Adachi T, Fujino H, Nakae A, et al. A meta-analysis of hypnosis for 
chronic pain problems: a comparison between hypnosis, standard 
care, and other psychological interventions. Int J Clin Exp Hypn 
2014;62:1–28.
 35. Kendrick C, Sliwinski J, Yu Y, et al. Hypnosis for acute procedural 
pain: a critical review. Int J Clin Exp Hypn 2016;64:75–115.
 36. Palsson OS, Turner MJ, Johnson DA, et al. Hypnosis treatment for 
severe irritable bowel syndrome: investigation of mechanism and 
effects on symptoms. Dig Dis Sci 2002;47:2605–14.
 37. Stewart JH. Hypnosis in contemporary medicine. Mayo Clin Proc 
2005;80:511–24.
 38. Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized 
clinical trial of a brief hypnosis intervention to control side effects in 
breast surgery patients. J Natl Cancer Inst 2007;99:1304–12.
 39. Xu Y, Cardeña E. Hypnosis as an adjunct therapy in the management 
of diabetes. Int J Clin Exp Hypn 2008;56:63–72.
 40. Golden WL. Cognitive hypnotherapy for anxiety disorders. Am J Clin 
Hypn 2012;54:263–74.
 41. Montgomery GH, Schnur JB, Kravits K. Hypnosis for cancer care: 
over 200 years young. CA Cancer J Clin 2013;63:31–44.
 42. Cheseaux N, de Saint Lager AJ, Walder B. Hypnosis before 
diagnostic or therapeutic medical procedures: a systematic review. 
Int J Clin Exp Hypn 2014;62:399–424.
 43. Corman I, Bouchema Y, Miquel B, et al. HypnosIS to faciLitate trans-
esophageal echocardiograPhy tolerance: the I-SLEPT study. Arch 
Cardiovasc Dis 2016;109:171–7.
 44. White CA. Cognitive behavioral principles in managing chronic 
disease. West J Med 2001;175:338–42.
 45. Halford J, Brown T. Cognitive-behavioural therapy as an adjunctive 
treatment in chronic physical illness. Advances in Psychiatric 
Treatment 2009;15:306–17.
 46. Morley S. Efficacy and effectiveness of cognitive behaviour 
therapy for chronic pain: progress and some challenges. Pain 
2011;152:S99–S106.
 47. Hofmann SG, Asnaani A, Vonk IJ, et al. The efficacy of cognitive 
behavioral therapy: a review of Meta-analyses. Cognit Ther Res 
2012;36:427–40.
 48. Ehde DM, Dillworth TM, Turner JA. Cognitive-behavioral therapy for 
individuals with chronic pain: efficacy, innovations, and directions for 
research. Am Psychol 2014;69:153–66.
 49. Jansen NW, Roosendaal G, Hooiveld MJ, et al. Theobald M, Lafeber 
FP. interleukin‐10 protects against blood‐induced joint damage. Br J 
Haematol 2008;142:953–61.
 50. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of 
proinflammatory cytokines in the pathophysiology of osteoarthritis. 
Nat Rev Rheumatol 2011;7:33–42.
 51. Valentino LA. Blood-induced joint disease: the pathophysiology of 
hemophilic arthropathy. J Thromb Haemost 2010;8:1895–902.
 52. Acharya SS. Exploration of the pathogenesis of haemophilic 
joint arthropathy: understanding implications for optimal clinical 
management. Br J Haematol 2012;156:13–23.
 53. Lee AS, Ellman MB, Yan D, et al. A current review of molecular 
mechanisms regarding osteoarthritis and pain. Gene 
2013;527:440–7.
 54. Oliveira CA, Velloso-Rodrigues C, Machado FC, et al. Cytokine 
profile and FVIII inhibitors development in haemophilia A. 
Haemophilia 2013;19:e139–e142.
 55. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine 
connection. Cytokine 2014;70:185–93.
 56. Pulles AE, Mastbergen SC, Schutgens RE, et al. Pathophysiology of 
hemophilic arthropathy and potential targets for therapy. Pharmacol 
Res 2017;115:192–9.
 57. Miller GE, Cohen S, Ritchey AK. Chronic psychological stress and 
the regulation of pro-inflammatory cytokines: a glucocorticoid-
resistance model. Health Psychol 2002;21:531–41.
 58. Campbell CM, Edwards RR. Mind-body interactions in pain: the 
neurophysiology of anxious and catastrophic pain-related thoughts. 
Transl Res 2009;153:97–101.
 59. Antoni MH, Lutgendorf SK, Blomberg B, et al. Cognitive-behavioral 
stress management reverses anxiety-related leukocyte transcriptional 
dynamics. Biol Psychiatry 2012;71:366–72.
 60. Cassis FR, Buzzi A, Forsyth A, et al. Haemophilia Experiences, 
Results and Opportunities (HERO) Study: influence of haemophilia 
on interpersonal relationships as reported by adults with 
haemophilia and parents of children with haemophilia. Haemophilia 
2014;20:e287–e295.
 61. Pai M, Key NS, Skinner M, et al. NHF-McMaster guideline 
on Care models for Haemophilia Management. Haemophilia 
2016;22(S3):6–16.
 62. Yates SL, Morley S, Eccleston C, et al. A scale for rating the quality 
of psychological trials for pain. Pain 2005;117:314–25.
 63. Boutron I, Moher D, Altman DG, et al. Extending the CONSORT 
statement to randomized trials of nonpharmacologic treatment: 
explanation and elaboration. Ann Intern Med 2008;148:295–309.
 64. Keefe FJ, Abernethy AP, C Campbell L. Psychological approaches to 
understanding and treating disease-related pain. Annu Rev Psychol 
2005;56:601–30.
 65. Jensen MP. A neuropsychological model of pain: research and 
clinical implications. J Pain 2010;11:2–12.
 66. Jensen MP. Psychosocial approaches to pain management: an 
organizational framework. Pain 2011;152:717–25.
 67. Green JP, Barabasz AF, Barrett D, et al. Forging ahead: the 
2003 APA Division 30 definition of hypnosis. Int J Clin Exp Hypn 
2005;53:259–64.
 68. Jensen MP, Patterson DR. Hypnotic approaches for chronic pain 
management: clinical implications of recent research findings. Am 
Psychol 2014;69:167–77.
 69. Weitzenhoffer AM, Hilgard ER. Stanford hypnotic susceptibility 
scale, form C (Vol. 27). Palo Alto, CA: Consulting Psychologists 
Press 1962.
 70. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain 
inventory. Ann Acad Med Singapore 1994;23:129–38.
 71. Remor E, Arranz P, Quintana M, et al. Psychometric field study of 
the new haemophilia quality of life questionnaire for adults: the 
'Hemofilia-QoL'. Haemophilia 2005;11:603–10.
 72. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983;67:361–70.
 73. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital anxiety 
and depression Scale. an updated literature review. J Psychosom 
Res 2002;52:69–77.
 74. Pais-Ribeiro J, Silva I, Ferreira T, et al. Validation study of a 
Portuguese version of the Hospital anxiety and depression Scale. 
Psychol Health Med 2007;12:225–37.
 75. Riley JL, Robinson ME. CSQ: five factors or fiction? Clin J Pain 
1997;13:156–62.
 76. Pinto PR, McIntyre T, Almeida A, et al. The mediating role of pain 
catastrophizing in the relationship between presurgical anxiety and 
acute postsurgical pain after hysterectomy. Pain 2012;153:218–26.
 77. Pinto PR, McIntyre T, Araújo-Soares V, et al. Differential predictors of 
acute post-surgical pain intensity after abdominal hysterectomy and 
Major joint arthroplasty. Ann Behav Med 2015;49:384–97.
 78. Pinto PR, McIntyre T, Nogueira-Silva C, et al. Risk factors for 
persistent postsurgical pain in women undergoing hysterectomy 
due to benign causes: a prospective predictive study. J Pain 
2012;13:1045–57.
 79. Moss-Morris R, Weinman J, Petrie K, et al. The revised illness 
perception questionnaire (IPQ-R). Psychol Health 2002;17:1–16.
 80. Figueiras M, Machado V, Alves N. Os modelos de senso-comum das 
cefaleias crónicas nos casais: relação com o ajustamento marital. 
Análise Psicológica 2002;1:77–90.
 81. Sniehotta FF, Gorski C, Araujo-Soares V. Adoption of community-
based cardiac rehabilitation programs and physical activity following 
phase III cardiac rehabilitation in Scotland: a prospective and 
predictive study. Psychol Health 2010;25:839–54.
 82. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol 
1993;30(3 Suppl 2):3–6.
 83. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of 
hemophilic arthropathy. Clin Orthop Relat Res 1980;149:153–9.
 84. Arbuckle JL. IBM SPSS AMOS 22 users' Guide: ibm Corp. 2013.
